Grant of Warrants to Genmab Employees Company

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Grant of Warrants to Genmab Employees

Company Announcement

Copenhagen, Denmark; October 15, 2014 – Genmab A/S (OMX: GEN) announced today that at a board meeting the board decided to issue 57,750 warrants to employees of the company as well as the company’s subsidiaries.

The exercise price for each warrant is DKK 220.40. Each warrant entitles the owner to subscribe one share of nominally DKK 1. On the basis of an exercise price of DKK 220.40 and by application of the Black-Scholes formula, the average value of each warrant can be calculated as DKK 83.91 based on an interest rate of 0.2760% and the historical volatility of Genmab A/S shares calculated at 47.27%.

The warrants vest in blocks of 25% one, two, three and four years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants were granted pursuant to the warrant plan adopted by the board on April 25, 2012. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Stock information > Warrants .

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications, a clinical pipeline with both late and early stage programs, and an innovative pre-clinical pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody™ platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates.  Partnering of selected innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com .

Contact:          
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo™; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody™ and UniBody ® . Arzerra ® is a registered trademark of the GSK group of companies.

Company Announcement no. 46
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 75

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 102

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 80

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 112

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 22

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 64

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 11

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 71

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading

Top 5 Most Recently Viewed Articles

TriPost Partners with Brixton Capital for Retail Expansion

Updated Category News Views 254

Strategic Partnership between TriPost and Brixton Capital TriPost Capital Partners, a real estate private equity firm, is thrilled to announce a significant partnership with Brixton Capital for acquiring a grocery-anchored retail portfolio. This collaboration focuses on high-quality investment opportunities in rapidly developing markets. Details of the Portfolio...

Continue Reading
Archer Aviation: Pioneering A New Era in Defense Technology

Updated Category News Views 200

Archer Aviation: A New Vision for Military Transportation When considering groundbreaking advancements in transportation, one might think of popular electric cars, but now there's a fresh contender: Archer Aviation Inc. This company stands out in the realm of electric vertical takeoff and landing aircraft (eVTOL), showcasing a vision that aligns with modern defense needs....

Continue Reading
Understanding Civil Claims for Rideshare Sexual Assault Victims

Updated Category News Views 279

Understanding Civil Claims for Rideshare Sexual Assault Victims Victims of sexual assault during rideshare trips have avenues to seek justice and compensation. With cases involving rideshare companies like Uber and Lyft, survivors might find themselves facing challenging circumstances after an assault. Fortunately, there are legal options available for those affected by...

Continue Reading
Ramsay Santé Optimizes Debt Structure with New TLB Reppricing

Updated Category News Views 242

Ramsay Santé Successfully Reprices Term Loans for Financial Growth Ramsay Santé recently achieved a significant milestone by repricing its €1,025 million Term Loan B4 (TLB4) and extending its €425 million Term Loan B3 (TLB3), effectively consolidating them into a new Term Loan B5. This strategic move is set to enhance their financial standing as part of their...

Continue Reading
NKGen Biotech to Present Innovative Research at Global Congress

Updated Category News Views 157

NKGen Biotech's Exciting Announcement on Upcoming Presentation NKGen Biotech Inc. (NASDAQ: NKGN), a pioneering clinical-stage biotechnology firm dedicated to developing cutting-edge autologous and allogeneic natural killer cell therapies, has recently shared some thrilling news regarding their participation in an international event. Highlighting Neurodegenerative...

Continue Reading